ArticleBMC cancer2021

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.

Chiao-En Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.